Journal of Dementia
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Editorial   
  • J Dement 7: 173,
  • DOI: 10.4172/dementia.1000173

Creutzfeldt - Jakob Disease from Prions to Neurodegeneration

Kaokaf Gonda*
Department of Psychiatry and Biobehavioral Science, UCLA School of Medicine, USA
*Corresponding Author : Kaokaf Gonda, Department of Psychiatry and Biobehavioral Science, UCLA School of Medicine, USA, Email: kaokaf.gonda@gmail.com

Received Date: Sep 02, 2023 / Published Date: Sep 28, 2023

Abstract

Dementia is a progressive neurodegenerative disorder that affects millions of people worldwide, causing cognitive decline, memory loss, and behavioral changes. While there is no cure for dementia, pharmacological treatments aim to manage symptoms and slow down disease progression. This article provides an overview of the current pharmacological options, including cholinesterase inhibitors and NMDA receptor antagonists, commonly used in dementia treatment. Additionally, it explores emerging therapies, such as anti-amyloid therapies, tau protein stabilizers, anti-inflammatory drugs, and neuroprotective agents, which hold promise for modifying the underlying pathology of dementia. Continued research in pharmacological interventions is crucial for developing more effective treatments and improving the lives of individuals affected by dementia.

Citation: Gonda K (2023) Creutzfeldt - Jakob Disease from Prions to Neurodegeneration. J Dement 7: 173. Doi: 10.4172/dementia.1000173

Copyright: © 2023 Gonda K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 567
  • [From(publication date): 0-2023 - Feb 23, 2025]
  • Breakdown by view type
  • HTML page views: 482
  • PDF downloads: 85
Top